Florian Föger is the founder of Cyprumed GmbH and the inventor of its next generation drug delivery technology. Previously, Florian Föger was Director of Oral Formulation Research at Novo Nordisk A/S in Denmark. He is the inventor of more than 10 patent applications in the field of oral peptide delivery and author of 17 peer reviewed research articles in the oral delivery field. Florian Föger received a PhD in Pharmaceutical Sciences from the University of Innsbruck, Austria.
Martin Werle, co-inventor of the Cyprumed technology, held various leadership and management positions in formulation development, corporate strategy and global R&D at Syngenta AG, Basel, Switzerland. In addition, he has many years of international experience as scientist and project leader in the area of oral peptide delivery, in both, academia and start-ups. Martin Werle has published more than 30 peer reviewed research articles and book contributions in the field of drug delivery. He received an MBA from SMC University, Switzerland and a PhD in Pharmaceutical Technology from the University of Innsbruck, Austria.
Jürg Meier was the Executive Director of the Novartis Venture Fund for eight years. Previously, he was working over 25 years in various international management functions of the former company Sandoz Pharma Ltd., holding positions such as Head of R&D Biochemie GmbH Austria, Head of R&D Sandoz USA and worldwide and President of Sandoz Pharma Japan. During eight years he was a member of the Swiss National Science Foundation and supervised three NCCR programs (National Centers of Competence in Research). Jürg Meier was Chairman of Polyphor AG and of Cardiolynx AG and a Board Member of Tecan AG, BioMed Invest AG and Solvias AG. Today Jürg Meier consults entrepreneurs and start-up companies.
Ruedi Wäger was the President and Chief Executive Officer of Aventis Behring L.L.C.. Previously, he was President and Chief Executive Officer of ZLB Central Laboratories, Blood Transfusion Service of Swiss Red Cross, and spent more than 20 years at Sandoz Ltd., where he had consecutive worldwide responsibilities for Strategic Research and Development Planning, Human Resource Management, and Marketing. Ruedi Wäger currently sits on the board of various biopharmaceutical companies. He earned a Ph.D. in Biochemistry from the Swiss Federal Institute of Technology.
Uwe Jacob was the main founder and first CEO of SuppreMol GmbH. Later he was holding the position of the Chief Scientific Officer and the Chief Development Officer. In parallel Uwe Jacob is teaching biochemistry at the Gene Center, Munich. Before working with SuppreMol he was assistant Professor at the Ludwig Maximilians University of Munich and a group leader at the Max Planck Institute of Biochemistry. Uwe Jacob studied biochemistry at the Medizinische Hochschule Hannover and the University of Southern California. He finalized his PhD thesis in X-ray crystallography in the department of Prof. Huber at the Max Planck Institute of Biochemistry. Afterwards Uwe Jacob continued his career as a post doctoral scientist at Roche Pharmaceuticals where he also finished his habilitation program.
